| Name | CLK-IN-T3 |
| Description | CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity. |
| In vitro | CLK-IN-T3 (0.5, 1.0 μM) decreases the phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. CLK-IN-T3 (0.1, 0.5, 1.0, 5.0, 10.0 µM) results in mild cell cycle arrest at the G2/M boundary with a long-duration of 24 h. CLK-IN-T3 inhibits DYRK1A and DYRK1B with IC50s of 260 and 230 nM[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (9.32 mM), Sonication and heating are recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.07 mM), Sonication is recommended.
|
| Keywords | stable | kinase | Inhibitor | inhibit | DYRK1B | DYRK1A | DYRK | Dual specificity tyrosine regulated kinase | Dual specificity tyrosine phosphorylation regulated kinase | Cyclin dependent kinase | CLK-IN-T-3 | CLK-IN-T3 | CLKINT3 | CLK3 | CLK2 | CLK1 | CLK IN T3 | CLK | CDK | CDC-like | anti-cancer | activity |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
